FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease
FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease
arcticnovartis
- Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient population
- PSMAddition updated results show Pluvicto reduced risk of progression or death by 33% in combination with standard of care (ADT + ARPI) vs. SoC alone, with positive overall survival trend (HR=0.80)
- mHSPC is incurable and about half of men progress within 20 months, highlighting need for differentiated, precision approaches earlier in disease journey